network member

Florida

About Network Member

Currently Enrolling

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
Cancer areas:Leukemia
AdventHealth Orlando
Rhode Island Hospital
University of North Carolina Lineberger Comprehensive Cancer Center
Currently Enrolling

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Cancer areas:Breast
Cleveland Clinic Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Memorial Breast Cancer Center at Memorial Regional Hospital
Memorial Sloan Kettering Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
Cancer areas:Basket
AdventHealth Orlando
CARTI
John Theurer Cancer Center at Hackensack Meridian Health
Meritus Center for Clinical Research / John R. Marsh Cancer Center
Salinas Valley Health
University of Louisville / James Graham Brown Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-GI23-643

Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer
Cancer areas:Colorectal
AdventHealth Orlando
UPMC Hillman Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Enrollment Closed

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
Cancer areas:Breast
Advocate Aurora Research Institute (Illinois)
Aurora Health Care
Froedtert & the Medical College of Wisconsin
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Miami Cancer Institute at Baptist Health, Inc.
Novant Health Oncology Specialists
The University of Chicago Medicine Comprehensive Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Enrollment Closed

HCRN-GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Cancer areas:Colorectal
Cleveland Clinic Cancer Center
Knight Cancer Institute at Oregon Health & Science University
Rutgers Cancer Institute of New Jersey
Sylvester Comprehensive Cancer Center at the University of Miami
The Ohio State University
University of Kansas Medical Center
Enrollment Closed

HCRN-LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Cancer areas:Lung
MD Anderson Cancer Center
Moffitt Cancer Center